Bar the windows but open the door to randomization

Journal of Clinical Oncology

Volumn 28, Issue 19, 2010, Pages 3104-3106

  Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; PAZOPANIB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

B CELL LYMPHOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; CHILD CARE; COLORECTAL CANCER; DRUG DESIGN; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; LUNG TUMOR; NEOPLASM; NONHODGKIN LYMPHOMA; NOTE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; NEOPLASMS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77955484542     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.3787     Document Type: Editorial

References (45)

1. Ettinger DS: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come. J Clin Oncol 8:374-377, 1990
2. Smith MA, Anderson BD: A window on reality? J Clin Oncol 22:1360-1362, 2004
3. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
4. Smith MA, Anderson B: Phase II window studies: 10 years of experience and counting. J Pediatr Hematol Oncol 23:334-337, 2001 (Pubitemid 32845657)
5. Wolff SN, Johnson DH, Hande KR, et al: High-dose etoposide as single-agent chemotherapy for small-cell carcinoma of the lung. Cancer Treat Rep 67:957-958, 1983 (Pubitemid 14231394)
6. Issell BF, Einhorn LH, Comis RL, et al: Multicenter Phase II trial of etoposide in refractory small-cell lung cancer. Cancer Treat Rep 69:127-128, 1985 (Pubitemid 15197092)
7. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989 (Pubitemid 19220137)
8. Buroker T, Padilla F, Groppe C, et al: Phase II evaluation of ftorafur in previously untreated colorectal cancer: A Southwest Oncology Group Study. Cancer 44:48-51, 1979 (Pubitemid 9234908)
9. Cowan JD, Von Hoff DD, McDonald B, et al: Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study. Cancer Treat Rep 66:1779-1780, 1982 (Pubitemid 12000639)
10. Aisner J: Identification of new drugs in small-cell lung cancer: Phase II agents first? Cancer Treat Rep 71:1131-1133, 1987
11. Blackstein M, Eisenhauer EA, Wierzbicki R, et al: Epirubicin in extensive small-cell lung cancer: A phase II study in previously untreated patients - A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 8:385-389, 1990 (Pubitemid 20087537)
12. Artal-Cortés A, Gomez-Codina J, Gonzalez-Larriba JL, et al: Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/ cisplatin in small-cell lung cancer. Clin Lung Cancer 6:175-183, 2004 (Pubitemid 39618642)
13. Costanza ME, Weiss RB, Henderson IC, et al: Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study - Cancer and Leukemia Group B 8642. J Clin Oncol 17:1397-1406, 1999 (Pubitemid 29220845)
14. Meinhardt A, Burkhardt B, Zimmermann M, et al: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 28:3115-3121, 2010
15. Altorki N, Lane ME, Bauer T, et al: Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non - small-cell lung cancer. J Clin Oncol 28:3131-3137, 2010
16. Burkhardt B, Zimmermann M, Oschlies I, et al: The impact of age and gender on biology, clinical features, and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39-49, 2005 (Pubitemid 43899706)
17. Rena O, Massera F, Robustellini M, et al: Use of the proposals of the international association for the study of lung cancer in the forthcoming edition of lung cancer staging system to predict long-term prognosis of operated patients. Cancer J 16:176-181, 2010
18. Vickers AJ, Ballen V, Scher HI: Setting the bar in phase II trials: The use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res 13:972-976, 2007
19. Van Glabbeke M, Steward W, Armand JP: Non-randomised phase II trials of drug combinations: Often meaningless, sometimes misleading - Are there alternative strategies? Eur J Cancer 38:635-638, 2002
20. Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445, 2004 (Pubitemid 41185107)
21. Ratain MJ: Phase II oncology trials: Let's be positive. Clin Cancer Res 11:5661-5662, 2005
22. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
23. Michaelis LC, Ratain MJ: Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 13:2400-2405, 2007
24. Ratain MJ, Karrison TG: Testing the wrong hypothesis in phase II oncology trials: There is a better alternative. Clin Cancer Res 13:781-782, 2007 (Pubitemid 46340347)
25. Stone A, Wheeler C, Barge A: Improving the design of phase II trials of cytostatic anticancer agents. Contemp Clin Trials 28:138-145, 2007 (Pubitemid 44937880)
26. Ratain MJ, Humphrey RW, Gordon GB, et al: Recommended changes to oncology clinical trial design: Revolution or evolution? Eur J Cancer 44:8-11, 2008 (Pubitemid 350258715)
27. Adjei AA, Christian M, Ivy P: Novel designs and end points for phase II clinical trials. Clin Cancer Res 15:1866-1872, 2009
28. Cannistra SA: Phase II trials in Journal of Clinical Oncology. J Clin Oncol 27:3073-3076, 2009
29. Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials: The importance of randomisation. Eur J Cancer 45:275-280, 2009
30. Sharma MR, Maitland ML, Ratain MJ: Other paradigms: Better treatments are identified by better trials - The value of randomized phase II studies. Cancer J 15:426-430, 2009
31. Seymour L, Ivy SP, Sargent D, et al: The design of phase II clinical trials testing cancer therapeutics: Consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16:1764-1769, 2010
32. Tang H, Foster NR, Grothey A, et al: Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 28:1936-1941, 2010
33. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001 (Pubitemid 32267972)
34. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006 (Pubitemid 46630490)
35. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002 (Pubitemid 35334752)
36. Péréz-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non - small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004 (Pubitemid 41103678)
37. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
38. DiMasi JA, Feldman L, Seckler A, et al: Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 87:272-277, 2010
39. Dancey JE, Dobbin KK, Groshen S, et al: Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16:1745-1755, 2010
40. Kádár B, Gombos K, Szele E, et al: Effects of isoflurane exposure on oncogene and tumour suppressor gene expressions in vital organs of CBA/CA mice. In Vivo 21:861-865, 2007
41. Hsiao PN, Chang MC, Cheng WF, et al: Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology 256:83-91, 2009
42. Guix M, Granja Nde M, Meszoely I, et al: Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 26:897-906, 2008 (Pubitemid 351398082)
43. Carden CP, Banerji U, Kaye SB, et al: From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther 85:131-133, 2009
44. Glassman RH, Ratain MJ: Biomarkers in early cancer drug development: Limited utility. Clin Pharmacol Ther 85:134-135, 2009
45. Wikipedia: Unknown/unknown. http://en.wikipedia.org/wiki/Unknown-unknown